Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Juvenile Rheumatoid Arthritis

This study has been completed.
Information provided by:
Swedish Orphan Biovitrum Identifier:
First received: May 17, 2002
Last updated: November 25, 2009
Last verified: February 2008

May 17, 2002
November 25, 2009
July 2000
November 2003   (Final data collection date for primary outcome measure)
The primary outcome of the study was to evaluate the safety of anakinra [ Time Frame: 28 weeks ]
Not Provided
Complete list of historical versions of study NCT00037648 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Juvenile Rheumatoid Arthritis
A Randomized, Multi-center, Blinded, Placebo-controlled Study With an Open-label Run-in Period to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daily, Single, Subcutaneous Injections of r-metHuIL-1ra (Anakinra) in Polyarticular-Course Juvenile Rheumatoid Arthritis
The purpose of this study is to determine the safety of anakinra in patients with Polyarticular-Course Juvenile Rheumatoid Arthritis, a form of rheumatoid arthritis affecting children.
Not Provided
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Juvenile Chronic Arthritis
  • Drug: Anakinra
  • Drug: Placebo
  • Placebo Comparator: placebo
    Intervention: Drug: Placebo
  • Experimental: anakinra
    Intervention: Drug: Anakinra
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
November 2003
November 2003   (Final data collection date for primary outcome measure)
  • Male or female age 2-17 yrs inclusive * Minimum weight 10 KG * Diagnosis of Chronic Arthritis
Sexes Eligible for Study: All
2 Years to 17 Years   (Child)
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
Not Provided
Not Provided
Not Provided
Not Provided
Global Development Leader, Amgen Inc.
Not Provided
Study Director: MD Amgen
Swedish Orphan Biovitrum
February 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP